Blinded Reader Training: How Trials Prepare Image Readers

Blinded reader training is the process that prepares independent image readers to interpret trial images the same way, using the same criteria, without knowing which treatment a participant received. A good program has four parts: a written imaging charter, training on the criteria and the modality, a certification test before any study data is read, and ongoing monitoring with retraining when readers drift. This guide walks through each part for sponsors, CRO project managers and study directors.

TL;DR

• Blinded readers interpret trial images without knowing the treatment assignment, and often without individual clinical data, so their reads are not shaped by expectations.
• The FDA’s imaging endpoint guidance points to an imaging charter as the place to define reader qualifications, training and bias controls.
• Strong programs train, test and certify readers before study reads begin, then keep checking them with masked replicate reads.
• Disagreement between readers is expected. What matters is that you measure it, adjudicate it by a set rule and retrain when the numbers call for it.
• Document everything: training records, qualifications, delegated tasks and any unblinding or deviation.

What a blinded reader does and why blinding matters

A blinded reader is an independent specialist who reads trial images, such as CT, MRI, X-ray or retinal photographs, and records findings against criteria the protocol defines. The reader is not a site investigator and does not know whether the participant is in the treatment or control arm.

The FDA’s guidance states that in a randomized controlled trial, readers of primary endpoint images will be blinded to treatment assignment because knowing it would be presumed to create bias. The same guidance notes that many, if not most, trials with imaging-based primary endpoints are run with no reader knowledge of individual-level clinical data, since that knowledge can also bias the read.

Blinding matters most in open-label studies. There, site clinicians know the assignment and the expected clinical course, so a site-based read can raise concern about bias. According to the same guidance, a fully blinded centralized interpretation process may greatly enhance the credibility of image assessments and better ensure consistency.

The extent of blinding is not identical in every study. The guidance says it depends on the role of imaging, the disease and clinical setting, and any unblinding effects of the investigational drug. In certain diseases, readers should also be blinded to the image acquisition date or to prior imaging observations. Your charter should say exactly which of these apply.

Why centralized reading depends on training

Training is the reason centralized reading can deliver uniform results. The FDA guidance says a centralized image interpretation process may provide more verifiable and uniform reader training and ongoing management of reader performance. That in turn helps quality control and can decrease variability in interpretations, leading to a more precise estimate of treatment effect.

Some image interpretation methods need centralized imaging for this reason alone. The guidance gives trial-specific measures of bone or joint disease in arthritic diseases as an example, where the extent of reader training recommended for specialized interpretation makes central reading the practical route.

If you are deciding where imaging fits in your overall design, our guide to integrated radiology in study design covers how imaging and laboratory data can be planned together from the start.

Start with the imaging charter

Reader training cannot be better than the document it teaches from. The FDA guidance recommends an imaging charter when trial-specific imaging standards are too extensive for the protocol. The charter should describe how sources of imaging bias and variability are controlled and how imaging process standards are put into practice for the trial design.

When you develop the charter, the guidance asks sponsors to consider:

• The number of readers and the background qualifications they need.
• The technical knowledge essential to interpret the images.
• Avoiding any other reader involvement in the trial, such as acting as an investigator, that might bias interpretation.
• The confidentiality of image reads.
• Reader fatigue and the use of substitute readers.

An academic review of endpoint assessment committees adds that the charter should cover the responsibilities of sponsor, CRO and independent readers, reader qualifications, the data required for review, interpretation guidelines, and data transfer and archiving. It also notes that for imaging studies the FDA encourages submitting the charter together with the complete protocol and final statistical analysis plan.

For a practical walk through turning that guidance into checks, see our article on imaging charters for trials.

What a reader training program contains

A grader training and certification program should be established before a central reading center starts a clinical study, according to a review of central reading center practices. It lists common features: reading center SOPs and protocols, background knowledge of the conditions being graded, detailed grading procedures for each modality, training sets reviewed with a senior grader, and modality-specific assessment and certification.

Translated into a working plan, the training curriculum usually has these modules:

1. Study overview. The goals of image interpretation, the endpoint, and what the reader’s decision feeds into.
2. Criteria and definitions. The response or grading criteria, any protocol-specific modifications, and image case report form conventions.
3. Modality and tools. How to manipulate images, take measurements and use the reading platform.
4. Worked cases. Training sets with accepted answers, reviewed with a senior reader.
5. Blinding rules. What the reader must never see or seek out, and what to do if information leaks.
6. Retraining procedures. When and how a reader is retrained.

The imaging charter checklist guidance derived from the FDA document makes a similar point: the reader training section should state the major goals of interpretation, expectations for image manipulation and lesion measurement, any unique read definitions and criteria, and how retraining works. Writing these into the charter keeps training consistent across readers and over time.

Qualifications before training

Training assumes a qualified starting point. A 2021 academic paper on reader performance from the oncology BICR literature describes initial reader training and follow-up retraining as corrective actions. Before that, the charter should set minimum credentials. The FDA guidance asks sponsors to specify the readers’ requisite background, so set the specialty, years of experience and modality expertise in writing and verify them before onboarding.

Certification: a worked example

The National Eye Institute’s Age-Related Eye Disease Study offers a documented model. Under its study protocol, graders were trained using a tutorial approach built on written protocols and teaching sets of photographs with established grades. After training, they had to become certified by passing grading tests covering a wide range of varieties and severities of the conditions.

Certification did not end onboarding. After certifying, new graders graded several reading lists of eyes already graded by experienced graders and compared their results. Those grades were not used as study data. They gave practice and showed where remediation was needed, with statistics on proportions of agreement and degrees of disagreement.

You can borrow this structure for any imaging modality: train, test against known answers, run a practice phase that does not count, and only then release the reader to live data.

Keep blinding intact in the reading workflow

Training readers to be blind is only half the job. The workflow has to keep them blind. An academic analysis of common errors in endpoint committees lists several operational mistakes that introduce potential bias:

• Unclear criteria for when a re-read is needed.
• Reviewers who are not independent of the sponsor and site personnel.
• Data that has not been anonymized.
• Unclear definitions of what data the committee should see.

Practical controls follow from this list. Strip identifiers and treatment codes from image headers and file names. Send readers only the data the charter allows. Hide acquisition dates and prior reads where the charter requires it. Keep reader communications with sites and sponsors to a defined channel. Our article on blinded lab results covers how trials hide and protect data more broadly, and the same principles carry over to image reads.

For teams mapping structured imaging results into submission datasets, our piece on DICOM SR for trials explains how to keep that mapping traceable.

Monitor readers throughout the study

Training at the start decays without monitoring. The AREDS quality control program has three components: initial training and certification, ongoing grading exercises with feedback, and masked replicate gradings of random samples to document grading variability.

Its monthly meetings show how this runs in practice. A senior grader selects a small sample of previously graded eyes with relevant abnormalities. Graders grade the sample masked, results are tabulated, and each grader sees their own results next to the group’s, especially the consensus.

Expect disagreement and measure it

Two independent readers will not always agree, and a good design plans for that. In a review of blinded independent central review in lung cancer trials, the average discrepancy rate was 34.3% at the time-point level and 59.2% at the patient level. Individual readers’ endorsement rates ranged from 27.7% to 77.8%. The authors found adjudication rates vary widely with the adjudication paradigm and the number of time points per patient. They propose reader-level endorsement rate as a useful KPI, and these metrics can trigger corrective actions such as retraining, with group sessions to discuss challenging cases and reach consensus.

A pooled analysis of 79 oncology trials reports that among 11 lung cancer trials, 38% of cases required adjudication. It also cites a 2009 review of 31 oncology trials where the two readers agreed on best radiographic response in 77% of cases and on the date of progression in 76%.

The lesson is not that readers are unreliable. It is that your charter should set the adjudication rule in advance, and your monitoring plan should track agreement by reader and by time period.

A simple monitoring plan

If memory recall could inflate consistency in repeat reads, say so in the charter and set the interval between reads accordingly. That is the guidance of the 2021 reader performance monitoring literature, which recommends describing recall in the charter.

Records to keep for the trial master file

Training that is not documented did not happen, as far as an inspector is concerned. For U.S. sites and sponsors, an academic regulatory documents presentation lists the essential documents that include training records, delegation of tasks and signature sheets, and protocol deviation logs.

For readers, keep at least:

• Current CVs and evidence of qualifications.
• Training materials, dates, attendance and versions used.
• Certification test results and practice-phase comparisons.
• Retraining records and the trigger that prompted them.
• Delegation of read tasks, including substitute readers.
• Records of any unblinding or blinding breach.

Good clinical practice standards, as summarized in an institutional SOP set, expect up-to-date CVs and documentation of training to remain available for review throughout the trial, with delegated tasks recorded in a delegation log. On unblinding, a major IRB’s investigator handbook says an investigator should promptly, within 30 days, document and explain any premature unblinding to the sponsor. Check which of these timelines your protocol and IRB adopt.

Perspective: why reader training belongs with your data plan

We see reader training go wrong most often when it is treated as a separate workstream from data logistics. Readers are trained on one version of the criteria, images arrive in another format, and the lab and imaging results land in different places. Every handoff is a chance for inconsistency or an accidental unblinding.

Our view is that a sponsor or CRO gains the most when specimen collection, laboratory results and imaging data are planned together, under one charter, with one set of blinding rules. That is the idea behind our integrated approach: radiology and laboratory services, courier pickup, regulatory-aligned data delivery and analysis-ready data bundles, built around the needs of each study.

Readers can only be as consistent as the data and instructions they receive. We design our delivery so your reading team gets what the charter allows, in a structure that supports traceable review.

Kohealth Labs

Support from a central laboratory partner

If your study needs laboratory and imaging data delivered in a form that supports blinded review, we can help plan that workflow. KoHealth Labs serves as a centralized laboratory and supplier partner for clinical trials, with specimen collection and management, biomarker analysis, regulatory-aligned data delivery and onboarding and training support designed around study-specific requirements.

See how our integrated clinical diagnostics for CROs and pharma fit into your protocol, or read our guide to AI data quality in clinical trials if analysis-ready data is your next planning question.

A pre-study checklist for sponsors and CROs

Before the first live read, confirm that you can answer yes to each of these:

1. Does the charter name reader qualifications, number of readers and substitute reader rules?
2. Is the level of blinding stated: treatment assignment, clinical data, acquisition date, prior reads?
3. Are reading criteria, image case report forms and protocol-specific modifications written down?
4. Is there a certification test with known answers, and a pass threshold?
5. Is there a practice phase whose reads do not count as study data?
6. Is the adjudication rule defined before the first read?
7. Do you have a schedule for masked replicate reads and reader-level KPIs?
8. Are retraining triggers and procedures documented?
9. Are reviewers independent of sponsor and site personnel, and are images anonymized?
10. Do you have a filing plan for training records, delegation logs and deviations?

FAQ

What is blinded reader training?

It is the preparation of independent image readers to apply trial criteria consistently while unaware of treatment assignment and, usually, individual clinical data. It typically includes training on the charter and criteria, a certification test, a non-counting practice phase and ongoing quality checks.

How is a reader certified before reading study data?

In the AREDS model, graders trained with written protocols and teaching sets, then passed grading tests covering a wide range of severities. After that they graded previously graded cases for practice, and those grades were not used as study data.

How often should reader performance be checked?

The charter should set the schedule. AREDS held monthly quality control sessions with masked samples and shared results. Whatever interval you choose, define it in advance, track reader-level agreement and name the thresholds that trigger retraining.

Do readers always agree, and what happens when they don’t?

No. Published BICR data shows meaningful discrepancy rates, so trials define an adjudication process in advance. Disagreements are tracked as a performance metric and discussed in group sessions to align interpretation of difficult cases.

Sources

• FDA, Clinical Trial Imaging Endpoint Process Standards Guidance for Industry (2018)
• Walovitch, Subjective endpoints in clinical trials
• The role of central reading centers: current practices
• NEI Age-Related Eye Disease Study protocol
• Beaumont et al., Blinded Independent Central Review (BICR) in New Therapeutic Lung Cancer Trials
• Ford et al., Adjudication Rates between Readers in Blinded Independent Central Review
• UNC, Essential Regulatory Documents
• Sterling IRB Handbook, Investigator section

For more information about our diagnostic testing, clinical research laboratory services, or partnership opportunities, visit https://kohealthlabs.com or contact KoHealth Labs at (469) 792-8439 and ask for Amy Patterson.